Detection of microscopic melanoma metastases in sentinel lymph nodes

Cancer

Volumn 86, Issue 4, 1999, Pages 617-627

  Yu, Lawrence L ^a,b   Flotte, Thomas J ^a   Tanabe, Kenneth K ^a   Gadd, Michele A ^a   Cosimi, A Benedict ^a   Sober, Arthur J ^a   Mihm Jr , Martin C ^a   Duncan, Lyn M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

MART 1; Melanoma; Metastasis; Sentinel lymph node

Indexed keywords

ANTIBODY; HEMATOXYLIN; PROTEIN S 100;

ARTICLE; CANCER STAGING; HUMAN; ISOTOPE LABELING; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, NEOPLASM; BIOPSY; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; TECHNETIUM TC 99M SULFUR COLLOID;

EID: 0033567077     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S     Document Type: Article

References (39)

1. Balch CM, Soong S-J, Shaw HM, Maddox WA, Urist MM, McCarthy WH, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch C, Houghton AN, Milton GW, Sober AJ, Soong S-J, editors. Cutaneous melanoma. 2nd edition. Philadelphia: J. B. Lippincott, 1992:165-87.
2. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Manual for staging of cancer. Philadelphia: J. B. Lippincott, 1992.
3. Essner R. The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma. Semin Oncol 1997;24(Suppl 4):S8-10.
4. Brady MS, Coit DG. Sentinel lymph node evaluation in melanoma. Arch Dermatol 1997;133:1014-20.
5. Miliotes G. The tumor biology of melanoma nodal metastases. Am Surg 1996;62:81-8.
6. Reintgen D, Cruse CW, Wells K, Berman C, Fenske N, Glass F, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994;220:759-67.
7. Ross M. The case for elective lymphadenectomy. Surgical Oncol Clin North Am 1992;1:205-22.
8. Piepkorn M, Weinstock MA, Barnhill RL. Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Arch Dermatol 1997;133:995-1002.
9. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
10. Crowley N. The case against elective lymphadenectomy. Surgical Oncol Clin North Am 1992;1:223-46.
11. Lingam MK, Mackie RM, McKay AJ. Intraoperative identification of sentinel lymph node in patients with malignant melanoma. Br J Cancer 1997;75:1505-8.
12. Tanabe K, Reintgen D. The role of sentinel lymph node mapping for melanoma. Adv Surg 1998;31:79-103.
13. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997;225:1-14.
14. Morton D, Wen D-R, Wong J, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.
15. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253-60.
16. Pickren J. Significance of occult metastasis a study of breast cancer. Cancer 1961;14:1266-71.
17. Saphir O, Amromin G. Obscure axillary lymph node metastasis in carcinoma of the breast. Cancer 1948;1:238-41.
18. Joseph E, Messina J, Glass F, Cruse CW, Rapaport DP, Berman C, et al. Radioguided surgery for the ultrastaging of the patient with melanoma. Cancer J Sci Am 1997;3: 341-5.
19. Kawakami Y, Battles JK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific anti-MART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1997;202:13-25.
20. Beaty M, Fetsch P, Wilder A, Marincola F, Abati A. Effusion cytology of malignant melanoma: a morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer 1997;81:57-63.
21. Wells C, Heryet A, Brochier J, Gatter K, Mason D. The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984;50:193-7.
22. Rosen P, Saigo P, Braun D, Weathers E, Fracchia A, Kinne D. Axillary micro-and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg 1981;194:585-91.
23. Fisher E, Swamidoss S, Lee C, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;42:2025-31.
24. Huvos A, Hutter R, Berg J. Significance of axillary macrometatases and micrometastases in mammary cancer. Ann Surg 1971;173:44-6.
25. Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
26. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793-6.
27. Heller R, Becker J, Wasselle J, Baekey P, Cruse W, Wells K, et al. Detection of submicroscopic lymph node metastases in patients with melanoma. Arch Surg 1991;126:1455-60.
28. Wang X, Heller R, VanVoorhis N, Cruse CW, Glass F, Fenske N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768-74.
29. van der Velde-Zimmerman D, Roijers J, Bouwens-Rombouts A, deWegner RA, deGraaf DW, Tilanus MGJ, et al. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996;149:759-64.
30. Ghossein R, Rosai J. Polymerase chain reaction in the detection of micrometastases and circulating tumour cells. Cancer 1996;78:10-6.
31. Ridolfi R, Rosen P, Thaler H. Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer 1977;39:164-71.
32. Cochran AJ, Wen DR, Herschman HR. Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int J Cancer 1984;34:159-63.
33. Cochran AJ, Wen D-R, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. Am I Surg Pathol 1988;12:612-8.
34. Wen D-R, Morton D, Cochran A. The pathology of melanoma patients with negative sentinel nodes who subsequently develop ipsilateral nodal metastasis. Mod Pathol 1997;10:48A.
35. Messina JL, Glass LF. Pathologic examination of the sentinel lymph node. J Fla Med Assoc 1997;84:153-6.
36. Zubovits L, Yu L, Duncan LM. S100, NK1/C3, HMB-45 and MART1 in metastatic melanoma. Mod Pathol 1999;12:66A.
37. Carson KF, Wen DR, Li PX, Lana AM, Bailly C, Morton DL, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996;20:834-40.
38. Wilkinson E, Hause L. Probability in lymph node sampling. Cancer 1974;33:1269-74.
39. Kirkwood JM, Ibrahim J, Sondak V, Erstoff M, Flaherty L, Smith T, et al. Role of high-dose IFN in high-risk melanoma: preliminary results of the E1690/s9111/C9190 US Intergroup postoperative adjuvant trial of high-and low-dose IFNa2b (HDI and LDI) in resected high-risk primary or regionally lymph node metastatic melanoma in relation to 10-year updated results of E1684. Proceedings of Advances in the Biology and Therapy of Cutaneous Melanoma, Boston, Massachusetts, November 6-7, 1998.